Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03740334 · ClinicalTrials.gov registry record · Phase 1

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

A Phase 1 study of Acute Lymphoblastic Leukemia (ALL), sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 1
Development phase
45
Enrollment target
12
Study locations

NCT03740334 is a Phase 1 study of Acute Lymphoblastic Leukemia (ALL) that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 45 participants, below the 6,303-participant average among 16 other Acute Lymphoblastic Leukemia (ALL) trials with a reported enrollment target (99% lower). The trial reports 12 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03740334, a Phase 1 study of Acute Lymphoblastic Leukemia (ALL), is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
45 participants
Enrollment target
12
Study locations

Study Summary

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: * ribociclib * everolimus * dexamethasone

Conditions Studied

Acute Lymphoblastic Leukemia (ALL)

Interventions

  • DRUG Everolimus
  • DRUG Dexamethasone
  • DRUG Ribociclib

Study Locations (12)

Massachusetts

  • Boston Children's Hospital - Boston
  • Dana Farber Cancer Institute - Boston
  • Dana-Farber Cancer Institute - Boston

New York

  • Roswell Park Cancer Institute - Buffalo
  • Memorial Sloan Kettering Cancer Center - New York

Colorado

  • Children's Hospital Colorado - Aurora

Delaware

  • Nemours/Alfred I. duPont Hospital for Children - Wilmington

Georgia

  • Children's Healthcare of Atlanta - Atlanta

Ohio

  • Cincinnati Children's Hospital Medical Center - Cincinnati

Pennsylvania

  • Children's Hospital of Philadelphia - Philadelphia

Texas

  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2019-01-30
Est. Completion 2026-10-01
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03740334

The ClinicalTrials.gov registry entry for NCT03740334 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 6,303-participant average among 16 other Acute Lymphoblastic Leukemia (ALL) trials with a reported enrollment target (99% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Acute Lymphoblastic Leukemia (ALL) appearing as the primary indexed condition, and to 3 interventions - of which Everolimus is the first listed.

NCT03740334 reports 12 study locations spanning 9 distinct geographic areas - top geographies include Massachusetts, New York, Colorado.

Frequently Asked Questions

What is clinical trial NCT03740334 about?

NCT03740334 is a clinical study titled "Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL". This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: * ribociclib * everolimus * dexamethason...

What is the current status of trial NCT03740334?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2019-01-30. Estimated completion is 2026-10-01.

What conditions does trial NCT03740334 study?

This clinical trial studies the following conditions: Acute Lymphoblastic Leukemia (ALL).

What interventions are being tested in trial NCT03740334?

The interventions under investigation include: Everolimus (DRUG), Dexamethasone (DRUG), Ribociclib (DRUG).

Who is sponsoring clinical trial NCT03740334?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03740334 being conducted?

This trial has 12 study locations across Colorado, Delaware, Georgia, Massachusetts, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Lymphoblastic Leukemia (ALL)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Lymphoblastic Leukemia (ALL)

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.